Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Details

Ressource 1Download: BIB_6DB572B57896.P001.pdf (1251.64 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_6DB572B57896
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Journal
Cancer
Author(s)
Luke J.J., Callahan M.K., Postow M.A., Romano E., Ramaiya N., Bluth M., Giobbie-Hurder A., Lawrence D.P., Ibrahim N., Ott P.A., Flaherty K.T., Sullivan R.J., Harding J.J., D'Angelo S., Dickson M., Schwartz G.K., Chapman P.B., Wolchok J.D., Hodi F.S., Carvajal R.D.
ISSN
1097-0142 (Electronic)
ISSN-L
0008-543X
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
119
Number
20
Pages
3687-3695
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish. pdf type: Original Article
Abstract
BACKGROUND: Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined.
METHODS: To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated.
RESULTS: Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival.
CONCLUSIONS: In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.
Pubmed
Web of science
Create date
17/11/2013 19:19
Last modification date
20/08/2019 15:27
Usage data